Uncategorized

Russia’s Biosimilar Powerhouse: BIOCAD’s Patent Pipeline and the Oncology Disruption No One in the West Is Watching

Russia’s biosimilar story is no longer a footnote—it’s a blueprint. And if you’re in pharma, biotech, investing, or policy, you should be paying attention now, not after the market share is already gone.
Here’s the agitation: while much of the West is …

Russia’s Biosimilar Powerhouse: BIOCAD’s Patent Pipeline and the Oncology Disruption No One in the West Is Watching Read Post »

Uncategorized

Read the Drug Patent Clock Before the Market Does: A step-by-step technical guide to forecasting pharmaceutical drug patent expiry for IP teams, R&D strategists, and institutional investors

The Drug Patent Clock Is Ticking—And IP Teams Are Often Forecasting in the Dark
Most IP teams don’t miss patent expiries because they can’t find them. They miss them because they can’t see the clock—the full chain of events that determines when exclusi…

Read the Drug Patent Clock Before the Market Does: A step-by-step technical guide to forecasting pharmaceutical drug patent expiry for IP teams, R&D strategists, and institutional investors Read Post »

Uncategorized

Drug Market Entry Intelligence: The Definitive Guide for Pharma Strategists, IP Teams, and Institutional Investors

Pharma’s next competitive edge won’t come from a new molecule—it’ll come from knowing when the market is about to change.
Drug development is hard. But market entry intelligence is harder to get right—and easier to get wrong.
In today’s environment—whe…

Drug Market Entry Intelligence: The Definitive Guide for Pharma Strategists, IP Teams, and Institutional Investors Read Post »

Biotechblog
Scroll to Top